Question-and-Answer Session
Operator
(Operator instructions) Our first question is from the line of Rick Rinkoff with Craig-Hallum.
Rick Rinkoff – Craig-Hallum
Well, congratulations on a better quarter than one before that. I had a couple of questions here, first of all you said the R&D includes a little bit of Merck. Could you tell us how much that was and why you’re being so forth coming could you tell us what Abbott was in the quarter?
Phil Ankeny
Yes. Rick, the Merck component was about a $1.2 million and on the Abbott front, we are not prepared to disclose that number, but we did articulate that it was down, down from a year ago.
Rick Rinkoff – Craig-Hallum
What was in the year ago?
Phil Ankeny
Well, the year ago we gave the full year number.
Rick Rinkoff – Craig-Hallum
Was it less than Merck this quarter?
Phil Ankeny
Not prepared to answer at that level.
Rick Rinkoff – Craig-Hallum
Okay. You talked about your big ophthalmology contract and then I believe you used the words extending the relation and what words did you use and what should we infer from that?
Bruce Barclay
I've already put my script away, Rick. So, I don’t remember exactly the words I used other than.
Rick Rinkoff – Craig-Hallum
Well, give us a new word.
Bruce Barclay
Other than as we mentioned in the last conference call we find a very significant agreement with the customer in a million of dollars for development activities and the team is very, very busy implementing those activities and doing a very nice job. In the course of that, this customer wants additional work and we are in the process of negotiating and we expect to be finalizing here in the not too distant future. Additional R&D contract for additional work again is expected to be in the millions of dollars.
Rick Rinkoff – Craig-Hallum
Okay. So they are expanding the agreement. They are not just extending it and maybe that was a misinterpretation I had. On that front ophthalmology was $3.7 million about how of it might have been in that customer?
Bruce Barclay
Getting back to expanding versus extending, I am not sure that I understand the difference other than, I am sure you understand the development programs the companies have began with In Vitro and animal and move forward. So, it's more like that, more long just extending the development process. If you want to call that expanding, that's fine.
- To read the full transcript on Seeking Alpha, click here »
